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Microvessel densitya b s t r a c t
Substance P (SP) is known to stimulate angiogenesis, fibroblasts proliferation and expressions of cytoki-
nes and growth factors involved in wound healing. However, SP level reduces in dermis in diabetics and,
hence, it was hypothesized that exogenously applied SP could be helpful in improving wound healing in
diabetic rats. Excision skin wound was created on the back of diabetic rats and rats were divided into
three groups i.e. (i) saline-, (ii) gel- and (iii) SP-treated. Normal saline, pluronic gel and SP (106 M) in
gel were topically applied once daily for 19 days. SP treatment significantly increased the wound closure,
levels of interleukin-10, and expressions of vascular endothelial growth factor, transforming growth
factor-beta1, heme oxygenase-1 and endothelial nitric oxide synthase, whereas it significantly decreased
the expression of tumor necrosis factor-alpha, interleukin-1beta and matrix metalloproteinases-9 in the
granulation/healing tissue. The inflammatory cells were present for long time in normal saline-treated
group. Histological evaluation revealed better extracellular matrix formation with marked fibroblast pro-
liferation and collagen deposition in SP-treated group. Early epithelial layer formation, increased
microvessel density and greater growth associated protein-43 positive nerve fibers were also evidenced
in SP-treated group. In conclusion, SP treatment markedly accelerated cutaneous wound healing in
diabetic rats.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
Diabetes mellitus (DM) is a very complex disease that drastical-
ly influences normal functioning of the affected individual includ-
ing wound healing process, which is markedly delayed. The most
common complications of delayed wound healing of diabetics
are: reduction in chemotactic and phagocytic activities of neu-
trophils [1], decreased vasculogenesis [2], decreased endothelial
nitric oxide synthase (eNOS) activity [3] and reduction of sub-
stance P (SP) level [4]. Abnormal nerve distribution and neuroin-
flammation are also connected with the chronic nonhealing
wounds in DM. The patients suffering from DM have diminished
number of nerves and depleted nerve growth factor in uninjured
skin and cutaneous wounds [5].SP, a 10-amino acid neuropeptide, is released by the sensory
nerve fibers during tissue insult and has been reported to be a
mediator of inflammation in wound healing [6]. It binds to
neurokinin-1 (NK-1) receptors and elicits vasodilatory action via
nitric oxide, alters vascular permeability and enhances the delivery
and accumulation of leukocytes to tissues for the expression of the
local immune response [7], SP stimulates the production of various
cytokines such as, tumor necrosis factor-alpha (TNF-a),
interleukin-1beta (IL-1b), IL-2, IL-8 and IL-6, and growth factors
namely, vascular endothelial growth factor (VEGF) and transform-
ing growth factor-beta1 (TGF-b1), involved in wound healing [8–
11]. It is also involved in the angiogenesis, epidermal cell prolif-
eration, and capillary and fibroblast proliferation [12,13].
Depleted SP and decreased number of SP-positive fibers has been
reported in the dermis of diabetic patients [4,14]. The reduction
of SP directly contributes to the abnormal healing response in
patients with diabetes [15]. SP has been shown to promote
cutaneous wound healing in non-diabetic rats [11,16]. Topical
application of SP (107 M) enhanced wound closure in nitric oxide
synthase knock out mice and non-diabetic rats [5,11]. In addition,
exogenously administration of SP stimulated fibroblast
Table 1
Description of primers used.
S. No. Gene Primer sequences Product size Annealing temp. (C) Accession number
1 b-actin F: 50-TCCTAGCACCATGAAGATCAA G-30 132 59 NC_005111
R: 50-GACTCATCGTACTCCTGCTTG-30
2 TGF-b1 F: 50-AAG TGG ATC CAC GAG CCC AA-30 246 62 NM021578.2
R: 50 GCTGCACTTGCAGGAGCGCA-30
3 VEGF F: 50-GCCAGCACATAGGAGAGATGAG-30 234 62 NM031836.2
R: 50 ACCGCCTTGGCTTGTCAC-30
4 TNF-a F: 50-GGCCACCACGCTCTTTCTGTCA-30 153 60 NM012675.3
R 50-TGGGCTACGGGCTTGTCACTC-30
5 IL-1b F: 50-GACAAGCAACGACAAAATCCC-30 124 58 NC_005102
R: 50-TGGGTATTGTTTGGGATCCAC-30
6 MMP-9 F: 50-CTTGAAGTCTCAGAAGGTGGATC-30 135 59 NC_005102
R: 50-CGCCAGAAGTATTTGTCATGG-30
7 IL-10 F: 50-CCTGCTCTTACTGGCTGGAG-30 161 60 NM012854.2
R: 50-TGTCCAGCTGGTCCTTCTTT-30
8 HO-1 F: 50-AGAGTCCCTCACAGACAGAGTTT-30 247 60 NM012580.2
R: 50-CCTGCAGAGAGAAGGCTACATGA-30
9 eNOS F: 50-TGATGTCACTATGGCAACCAG-30 145 59 NC_005103
R: 50-TGTGAGTCCGAAAATGTCCTC-30
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Achilles tendon healing in rats [13]. In view of the above, we
hypothesized that topical supplementation of SP might be helpful
in improving impaired wound healing in diabetics. Thus, the pre-
sent study was planned to investigate the time-dependent effects
of topically applied SP in open excision wound in diabetic rats.
Additionally, we used pluronic F-127 (PF-127) gel for the topical
delivery of SP at the wound site, as we found [17] that PF-127
gel markedly improved wound healing in non-diabetic rats.2. Experimental procedures
2.1. Experimental animals and diabetes induction
Healthy adult male Wistar rats (170–200 g) were procured from
Laboratory Animal Resource Section, Indian Veterinary Research
Institute, Izatnagar (U.P.), India. The experimental protocol was
approved by the Institute Animal Ethics Committee. All animals
received humane care in accordance with National Institutes of
Health’s Guide for the Care and Use of Laboratory Animals (NIH
Publication N. 85-23, revised 1985). Diabetes was induced by sin-
gle intraperitoneal injection of streptozotocin (60 mg/kg;
Sigma-Aldrich, USA). After 48 h, animals with blood glucose levels
P300 mg/dl were selected. After 7 days of diabetic induction, the
open excision-type wound 2  2 cm2 (400 mm2, 2 mm depth
including the panniculus carnosus) was created on the back of
sixty diabetic animals under pentobarbitone sodium (40 mg/kg)
anesthesia. Following recovery from anesthesia, rats were housed
individually in properly disinfected cages.
2.2. Grouping
Animals were divided equally in the following three groups:
(I) Control: Sterile normal saline was applied on the wounds
once daily for 19 days.
(II) PF-127 gel-treated (gel-treated): 400 ll of PF-127 gel (25%,
Sigma Aldrich, USA) was applied topically once daily for
19 days.
(III) SP-treated: 400 ll of SP (106M, Sigma Aldrich) in PF-127 gel
(25%) was applied topically on wounds once daily for
19 days.2.3. Photography and wound contraction
Photograph of each wound was taken on days 0, 3, 7, 11, 14 and
19 post-wounding. The wound area was determined planimetrical-
ly on these days and per cent wound contraction was calculated by
Wilson’s formula as follows:
% wound contraction
¼ 0 day wound areawound area on particular day
0 day wound area
 1002.4. Tissue harvesting
Five animals from each group were killed on days 3, 7, 14 and
19, and granulation/healing tissue was collected. One portion
was stored in RNA stabilization reagent (RNAlater™, Qiagen, USA)
at 20 C until RNA extraction. The second portion was preserved
in 10% neutral buffer formalin for histopathological evaluation.
Third portion was homogenized in ice-cold lysis buffer [100 mg tis-
sue in 1 ml lysis buffer: 1% Triton X 100, 10 mM phenylmethylsul-
fonyl fluoride, 1 mg/ml aprotinin and 1 mg/ml leupeptin in
phosphate buffer saline (pH 7.4)] and centrifuged at 12,000 rpm
for 10 min at 4 C. The aliquots of the supernatant were prepared
and stored at 80 C till further processing for Western blotting
and enzyme linked immunosorbant assay (ELISA).
2.5. Real-time RT-PCR
The mRNA expressions of TNF-a, IL-10, TGF-b1, VEGF, IL-1b,
matrix metalloproteinases-9 (MMP-9), heme oxygenase-1 (HO-1)
and eNOS were determined with real-time RT-PCR. RNA was isolat-
ed from wound tissues using RibozolTM RNA extraction reagents
(Amresco, USA) and cDNA was synthesized using cDNA synthesis
kit (Fermentas, Lafayette, CO, USA). cDNA was used as a template
for the subsequent real time RT-PCR. The real time PCR assay
was performed by using 2  QuantiTect SYBR Green PCR Master
Mix, (Qiagen, CA, USA) in CFX96 real time PCR DET SYS (C-1000
thermal cycler, BIO-RAD laboratories India). The real-time RT-PCR
experiment was carried out according to the manufacturer’s
instruction and the following thermal cycling profile was used
(40 cycles): 95 C for 15 min, 94 C for 15 s, 58–62 C (depending
on primer) for 30 s and 72 C for 30 s. Details of the primers used
Table 2
Fasting blood glucose levels in different groups before (normal blood glucose) and after administration of streptozotocin (STZ; 60 mg/kg body wt.) injection (n = 5).
Group Day 0 (STZ
injected)










Control 102.6 ± 6.42a 424.4 ± 33.81b 464.2 ± 34.37b 440.2 ± 26.08b 427.8 ± 24.25b 424.8 ± 20.39b 478.8 ± 15.66b
Gel 102.4 ± 4.23aa 434.4 ± 30.24b 444.8 ± 30.58b 448.8 ± 33.41b 446.2 ± 25.86b 432.4 ± 22.06b 417.6 ± 16.73b
SP 98.6 ± 5.87a 466.6 ± 33.61b 475.8 ± 35.01b 439.6 ± 24.71b 451.2 ± 31.64b 447.8 ± 20.69b 425.8 ± 19.28b
Blood glucose levels were compared to day 0 levels of the same group. Values with different superscripts (i.e. ’a’ and ’b’) vary significantly.
b p < 0.001.
Fig. 1. Effect of substance P (SP) on increased cutaneous wound closure. (A) Representative photographs of wounds of control, gel-treated and SP-treated groups revealing
faster wound closure in SP-treated group. (B) Wound contraction (%) in different groups on days 3, 7, 11, 14 and 19 post-wounding. SP markedly increased the per cent wound
contraction on days 7, 11, 14 and 19, as compared to other groups. ⁄p < 0.05, ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 indicate significant difference compared with other group(s) on the
same day. The data expressed are an average means ± SEM, n = 5.
146 V. Kant et al. / Cytokine 73 (2015) 144–155are given in Table 1. The DDCT method of relative quantification
was used to determine fold change in expression and was obtained
as 2DDCT [18].
2.6. Western blotting
The expression levels of VEGF and TGF-b1 were determined by
Western analysis. Proteins were separated by using SDS-PAGE
and transferred to polyvinylidene difluoride membrane. The mem-
branes were then incubated with goat polyclonal antibodies again-
st VEGF and TGF-b1 (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). After washing, membranes were incubated with horseradish
peroxidase (HRP)-conjugated chicken anti-goat IgG (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). b-actin was used to normalize
protein loading. The blots were subsequently scanned and bandintensity was quantified by densitometry software (ImageJ, NIH).
Four minimum such blots were performed for every protein
analyzed.
2.7. ELISA
The supernatants of lysates were quantitatively assayed for
TNF-a and IL-10 (Komabiotech Inc., Seoul, Korea) levels as per
the manufacturer’s instructions.
2.8. Hematoxylin and Eosin (H&E) staining
5 lm thick tissue sections were stained with H & E as per stan-
dard method and visualized under light microscope (Leica
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Fig. 2. Effect of substance P (SP) on mRNA expressions and protein levels of TNF-a and IL-10. (A) mRNA expressions of TNF-a in different groups on various days. The TNF-a
mRNA expression was significantly lower on days 7, 14 and 19 in SP-treated wounds, as compared to control group. (B) mRNA expressions of IL-10 in different groups on
various days. The IL-10 mRNA expression was markedly lower in control wounds, as compared to others. The mRNA expressions were normalized by b-actin at each time
point and data are expressed as means ± SEM fold change (n = 4). (C) The TNF-a levels in different groups on various days and significantly lower levels on days 7, 14 and 19 in
SP-treated wounds supports the mRNA results. (D) The IL-10 levels in different groups on various days and significantly higher levels were found on days 7, 14 and 19 in SP-
treated wounds, as compared to control group. Data are expressed as means ± SEM (n = 5). ⁄p < 0.05, ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 vs other group(s) on the same day.
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evaluated and scoring was done according to the method of
Greenhalgh et al. [19] with some modifications. Briefly, scoring
for each field was done from 1 to 15. The fields showing none to
very less amount of inflammatory cell accumulation and granula-
tion tissue were scored from 1 to 3. Score of 4–6 was given to
the fields showing thin immature granulation tissue, which was
dominated by inflammatory cells, few fibroblasts, blood vessels
and collagen deposition. Score of 7–9 was assigned to the fields
which showed moderate thick granulation tissue dominated by
more fibroblasts and collagen deposition, more neovascularization,
minimal to moderate epithelial layer formation and few inflamma-
tory cells. Score of 10–12 was given to thick, vascular granulation
tissue, which was dominated by fibroblasts with extensive extra-
cellular collagen deposition and enveloped by partially immature
to completely formed epithelial layer. Scoring 13–15 was given
to the fields showing thick mature granulation tissue dominated
by compact collagen deposition parallel to the well formed com-
plete epithelial layer and decreased fibroblasts and blood vessels
to normal.
2.9. Immunohistochemistry for CD31 and growth associated
protein-43 (GAP-43)
Sections were immunostained for CD31 for neovascularization
and GAP-43 for axonal regeneration by incubating with respectiveprimary mouse monoclonal antibody (Novus Biologicals, Littleton,
CO, USA) and HRP-conjugated goat anti mouse IgG (Santa Cruz
Biotechnology). The aminoethylcarbazole (AEC) was used as chro-
mogen substrate (AEC Staining Kit; Sigma-Aldrich, USA).
Microphotographs were captured (Leica DFC450C) and twenty ran-
dom fields were observed (40) for the semi-quantitative analysis
of microvessel density (MVD). However, thirty fields were
observed (40) for the quantification of GAP-43 positive nerve
fibers.
2.10. Picrosirius red staining
Assessment of collagen in wound sections was done by staining
with picrosirius red (Direct Red 80, Sigma Aldrich, USA) by modi-
fied picrosirius procedure [20]. Stained sections were viewed
under polarized light (Leica DM2500P) and quantitative study of
images for total collagen fraction was done in eight random images
(20) from each group by using ImageJ software.
2.11. Statistical analysis
All data are expressed as mean ± standard error and data were
analyzed by two way analysis of variance (ANOVA) followed by
Bonferroni’s post test using the GraphPad Prism v4.03 software
program (San Diego, CA, USA), and the statistically significant
differences were considered at p < 0.05.
Fig. 3. Effect of substance P (SP) on mRNA and protein expressions of VEGF and TGF-b1. (A) and (B) The mRNA expressions of VEGF and TGF-b1, respectively, in different
groups on various days. The VEGF and TGF-b1 mRNA expressions were significantly increased on days 3 and 7 in SP-treated wounds. The mRNA expressions were normalized
by b-actin at each time point and data are expressed as means ± SEM fold change (n = 4). (C) Representative Western blots of b-actin, VEGF and TGF-b1 from the homogenate
samples of control (c), gel- and SP-treated rats on days 3, 7, 14 and 19 post-wounding. (D) and (E) The semiquantitative protein expressions of VEGF and TGF-b1 in wounds of
different groups on various days. The VEGF expression was significantly higher on day 7 and TGF-b1 expression was higher on days 3 and 7 in SP-treated wounds. The
increased expression of these proteins supports the mRNA results. The values of each protein expressions were corrected for corresponding b-actin for the expression as
normalized protein levels. Data are expressed as means ± SEM (n = 4). ⁄p < 0.05, ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 vs other group(s) on the same day.
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The animals used in the present study showed the signs of the
diabetes from second day after administration of streptozotocin.
The blood glucose levels significantly increased in all the groups
after 48 h of administration of streptozotocin and the levels
remained significantly elevated during the entire experiment
(Table 2). Other signs like loss of body weight, polyphagia, polydip-
sia, polyuria, increased ocular discharge and paraphimosis with
bluish coloration of glans penis were also observed.
Grossly, healing of wound was better in SP-treated group,
which was evidenced by early formation and shedding of scab.
Well formed and thick red granulation tissue was also distinguish-
able in SP-treated rats at the time of tissue collection particularly
on days 3 and 7 post-wounding.
3.1. Wound closure
Gross evaluation of wound revealed that topical application of
SP decreased the wound size (Fig. 1A) with significantly increasedper cent wound contraction (Fig. 1B), as compared to other groups.
The mean per cent wound contraction of SP-treated group was
markedly more from control and gel-treated group on day 7 and
this difference continued till day 19 after wound creation. The
gel-treated group also showed significantly increased wound
contraction on day 11 and 14, as compared to control.
3.2. mRNA expressions and protein expressions/levels of TNF-a, IL-10,
VEGF and TGF-b1
Relative mRNA expression of TNF-a significantly decreased in
SP- and gel-treated groups on days 7, 14 and 19 post-wounding,
as compared to control (Fig. 2A). TNF-a levels were lower in
SP-treated group on days 7, 14 and 19 (Fig. 2C). The mRNA expres-
sion of IL-10 did not increase markedly in gel- and SP-treated
groups (Fig. 2B). However, IL-10 levels increased significantly in
SP-treated group on days 7, 14 and 19, as compared to control
(Fig. 2D).
VEGF mRNA expression was markedly higher in SP-treated
group on day 3 and 7, as compared to control (Fig. 3A). VEGF
Fig. 4. Effect of substance P (SP) on mRNA expressions of IL-1b, MMP-9, HO-1 and eNOS. (A) and (B) The mRNA expressions of IL-1b and MMP-9, respectively, in different
groups on various days. The IL-1b and MMP-9 expressions were significantly lesser in SP- and gel-treated group on days 14 and 19, as compared to control. (C) The mRNA
expressions of HO-1 in different groups on various days and the HO-1 expression were significantly up-regulated by SP-treated wounds on days 3 and 7, as compared to
control. (D) The mRNA expressions of eNOS in different groups on various days and the eNOS expression were significantly higher throughout the experiment in SP-treated
group, as compared to control. The mRNA expressions were normalized by b-actin at each time point and data are expressed as means ± SEM fold change (n = 4). ⁄p < 0.05,
⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 indicate significant difference compared with other group(s) on the same day.
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SP-treated group on day 7, as compared to control and
gel-treated rats (Fig. 3D). mRNA expression of TGF-b1 was sig-
nificantly up-regulated on days 3 and 7 in SP-treated group
(Fig. 3B). The TGF-b1 protein expression (Fig. 3E) was also
increased significantly in SP-treated group on days 3 and 7.
3.3. mRNA expression of IL-1b, MMP-9, HO-1 and eNOS
The mRNA expression of IL-1b (Fig. 4A) and MMP-9 (Fig. 4B)
were significantly decreased on days 14 and 19 in SP-treated
group, as compared to control. Moreover, the mRNA expression
of HO-1 was significantly increased on day 3 and 7 in SP group
(Fig. 4C). The expression of eNOS was significantly higher in
SP-treated group during the entire experiment (Fig. 4D).
3.4. H & E staining
The representative images of H & E-stained wound sections are
presented in Fig. 5A (40) and inset boxes represent lower magni-
fication (10). On day 3, SP-treated wounds comparatively showed
more fibroblast with few inflammatory cells. On day 7, in control
group, lower part of wound area covered by fibro fatty connective
tissue (fat cells) and superficial area showed marked inflammatory
changes within proliferative fibrous tissue. However, in SP-treated
group, wound area covered by well formed granulation tissue with
marked proliferation of fibroblasts, and new and well formed
capillaries.
On day 14, SP-treated group showed well formed granulation
tissue with collagen deposition and covered by newly formed
epithelial layer. Whereas, control group still showed presenceof marked inflammatory cells. On day 19, in SP-treated group,
wound area covered by fibroblasts with compact well oriented
collagen deposition and few macrophages. There was formation
of complete and thick regenerated epithelial layer covering the
healed tissue. The wound area of control group still showed
prominent inflammatory reaction in upper part, whereas, lower
part showed granulation tissue with collagen deposition.
Gel-treated group depicted wound area enclosed by fibroblasts
with prominent collagen deposition and covered by superficial
epithelial layer. Histological scoring revealed significantly higher
score of SP-treated group, as compared to other groups (Fig. 5B).
3.5. Neovascularization at wound site by immunostaining for CD31
The representative images of CD31-positive vessels are present-
ed in Fig. 6A (40) and inset boxes correspond to lower magnifica-
tion (10). The neovascularization was greater and better in
SP-treated group, whereas, newly forming blood vessels were uni-
formly distributed within granulation tissue with well marked
lumen of the vessels and large perimeter. However, in other
groups, particularly in control group, the neovascularization was
uneven, aberrant and frustrated in nature. The lumen of the
vessels was not well marked and vascular occlusion was
observed. The microvessel density in SP-treated group was sig-
nificantly increased on days 3, 7 and 14, and decreased on day
19 (Fig. 6B).
3.6. GAP-43 positive nerve fibers
The representative images of GAP-43 positive fibers are pre-
sented in Fig. 7A (40). The positive fibers were more in the vessels
Fig. 5. Effect of substance P (SP) on histological changes in the granulation/healing tissues on days 3, 7, 14 and 19 post-wounding. (A) Representative images of H & E stained
wound sections of different groups on days 3, 7, 14 and 19 post-wounding (40magnification and scale bar 50 lm). Low magnification (10) images of wounds are shown in
inset boxes in the left upper corner. SP-treated wounds comparatively showed more fibroblast with few inflammatory cells on day 3. On day 7, wounds of SP-treated group
were covered by well formed granulation tissue with marked proliferation of fibroblasts, and new and well formed capillaries. However, in control group, inflammatory
changes were observable within proliferative fibrous tissue in superficial area. On day 14, SP-treated group showed well formed granulation tissue with collagen deposition
and covered by newly formed epithelial layer, as compared to marked presence of marked inflammatory cells in control group. On day 19, wound area of SP-treated group
showed presence of fibroblasts with compact collagen deposition, and complete and thick regenerated epithelial layer covering the healed tissue was also evident. However,
the wound area of control group still showed prominent inflammatory reaction in upper part, whereas, lower part showed granulation tissue with collagen deposition. I:
inflammatory cells; F: fibroblasts; BV: blood vessels; FC: fat cells; C: collagen; E: epithelial layer. (B) Histological scoring of H & E stained wound sections. Histological scoring
revealed significantly higher score of SP-treated group, as compared to other groups. The data expressed are an average means ± SEM (n = 10). ⁄p < 0.05, ⁄⁄p < 0.01 and
⁄⁄⁄p < 0.001 indicate significant difference compared with other group(s) on the same day.
150 V. Kant et al. / Cytokine 73 (2015) 144–155and hypodermis. The quantification revealed more GAP-43 positive
fibers in SP-treated group and number was significantly higher on
day 14 (Fig. 7B).3.7. Collagen synthesis and deposition
The representative pictures of picrosirius red stained sections
are shown in Fig. 8A. The collagen fraction (%) increased in all
the three groups in time-dependent manner with no significant
difference between groups (Fig. 8B). Apparently, synthesis, deposi-
tion, compactness, orientation and organization of collagen weremuch better in SP-treated wounds, as compared to other groups
on respective days.4. Discussion
The findings of our study showed markedly decreased expres-
sion/levels of TNF-a, IL-1b and MMP-9 and increase IL-10 levels
in SP-treated group in comparison to control group. SP also
increased the expressions of VEGF, TGF-b1, SDF-1a, HO-1 and
eNOS. In addition, histologically better granulation tissue with
marked fibroblast proliferation, increased MVD, compact collagen
Fig. 6. Effect of substance P (SP) on neovascularogenesis at wound site on different days of treatment. (A) Representative immunohistochemical CD31 stained wound sections
of control, gel-treated and SP-treated rats [40magnification and scale bar 50 lm; low magnification (10) images are in inset boxes]. The newly forming blood vessels were
uniformly distributed within granulation tissue with well marked lumen of the vessels and large perimeter in SP-treated wounds. However, in other groups, particularly in
control group, the neovascularization was uneven, aberrant and frustrated in nature. The lumen of the vessels was not well marked and vascular occlusion was observed in
control group. (B) Semiquantitative analysis of microvessel density (MVD) (n = 20). MVD was assessed by counting the number of CD31 positive microvessels in high-power
fields (HPFs) (40). The MVD in SP-treated group was significantly increased on days 3, 7 and 14, and decreased on day 19. The data expressed are an average means ± SEM,
n = 20. ⁄p < 0.05, and ⁄⁄⁄p < 0.001 indicate significant difference compared with other group(s) on the same day.
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denced in SP-treated group. The results are suggestive of sig-
nificantly better wound closure in SP-treated rats. Progressively,
better wound closure is duly represented by the photographs
(Fig. 1A).
Normal wound healing process gets impaired in diabetes due to
the alterations in interaction between cytokines and neuropeptides
[21]. Hyperglycemia has been found to interrupts the action of vital
inflammatory mediators in wound healing [21] and persistent
inflammation is responsible for delay in granulation tissue forma-
tion and failure of wound closure in diabetes [22,23]. In order to
evaluate the effect of once daily topical application of SP on persis-
tent inflammation, we measured the expressions/levels of TNF-a,IL-1b and MMP-9 in the granulation/healing tissues of diabetic rats
on different days. SP caused marked reduction in the expres-
sion/levels of TNF-a (Fig. 2A and C), IL-1b (Fig. 4A) and MMP-9
(Fig. 4B) on days 14 and 19 post-wounding, which suggests
the marked reduction of inflammatory state at wound site,
as compared to control.
Macrophages play a pivotal role in wound healing due to their
capacity to produce inflammatory cytokines and growth factors
[24,25]. The macrophages should change their phenotype from
M1 (pro-inflammatory in nature and produce more TNF-a, IL-1b,
IL-6, or IL-12) to M2 (anti-inflammatory/angiogenic in nature and
are prominent source of TGF-b) during the normal healing
process [26–28]. So, the failure in switching of M1 to
Fig. 7. Effect of substance P (SP) on axonal regeneration. (A) Representative immunohistochemical GAP-43 stained wound sections (40magnification and scale bar 50 lm).
The positive fibers were more in the vessels and hypodermis region in SP-treated group. (B) Semiquantitative analysis of GAP-43 positive nerve fibers in random high-power
fields (HPFs) (40). The quantification revealed that the number of GAP-43 positive fibers was significantly higher on day 14 in SP-treated group. The data expressed are an
average means ± SEM, n = 30. ⁄p < 0.05, ⁄⁄p < 0.01 and ⁄⁄⁄p < 0.001 indicate significant difference compared with other group(s) on the same day.
152 V. Kant et al. / Cytokine 73 (2015) 144–155anti-inflammatory/angiogenic M2 macrophages, which is common
in diabetic wound, leads to increased expression of TNF-a and
decreased expression of IL-10 and results in impaired healing
[29–33].
In present study, SP application might caused appropriate
switching of the M1 to M2 macrophages, which in turn decreased
the expression and levels of TNF-a in SP-treated group, as com-
pared to other group after day 3 post-wounding. So, SP efficiently
induces acute inflammation at early stage and reduces it in later
stages, which is essential for a good skin repair. This is in agree-
ment with the earlier studies by Leal et al. [34] and Jiang et al. [35].
To further support these effects of SP, we assayed the expres-
sion/levels of HO-1, IL-10, and TGF-b1. The expressions of HO-1
(Fig. 4C) and TGF-b1 (Fig. 3B and D) were up-regulated by SP on
days 3 and 7. However, the levels of IL-10 were increased on days
7, 14 and 19 by SP application (Fig. 2D). HO-1 has been shown as an
anti-inflammatory enzyme [36] and SP induces its expression [37].IL-10 ([38,39] and TGF-b [40] also possess anti-inflammatory activ-
ity and SP has been shown to increase TGF-b [11] and IL-10 [11,41]
expressions/levels. Moreover, H & E staining evidently showed that
SP markedly and progressively reduce the inflammatory cells at
wound site until day 19, as compared to control and gel-treated
group (Fig. 5A). These results suggest that SP efficiently abolishes
the persistence of inflammatory state at wound site in diabetic
rats.
Inhibition of angiogenesis impairs wound healing. VEGF and
TGF-b1 are involved in stimulation, promotion and stabilization
of new blood vessels [42]. VEGF induces angiogenesis by promot-
ing endothelial cell proliferation and prevent their apoptosis [43].
TGF-b has also been connected to neovascularization pathways
through several mechanisms. It activates the recruitment of
VEGF-expressing hematopoietic effector cells, which establishes a
potent signaling set-up in inflammatory wound environment that























Fig. 8. Effect of substance P (SP) on collagen synthesis and arrangement. (A) Picrosirius red stained histological sections of cutaneous wound showing collagen fibers under
polarized light on days 3, 7, 14 and 19 post-wounding in control, gel-treated and SP-treated rats. Collagen formation as well as arrangement was better in the SP-treated
group, as compared to other groups on respective days. Scale bar 100 lm and magnification 20. (B) Average fraction of total collagen fibers in picrosirius red stained
histological wound sections of control, gel-treated and SP-treated rats on days 3, 7, 14 and 19 post-wounding. The collagen fraction (%) increased in all the three groups in
time-dependent manner with no significant difference between groups The data expressed are an average means ± SEM, n = 8.
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present study, SP significantly increases the expressions of VEGF
(Fig. 3A and C) and TGF-b1 (Fig. 3B and D), as compared to control
and gel-treated group. This supports the appropriate angiogenic
response at wound site in SP-treated group. This was supported
by the increased MVD at wound site in SP-treated group
(Fig. 6B), which was confirmed by the immunohistochemistry ofCD31 (Fig. 6A). However, decreased MVD and abnormal angio-
genesis in control diabetic group consequently delayed wound
repair in the present study, which is in agreement with the earlier
report [47]. Thus, application of SP seems to restore angiogenesis,
with increased, evenly distributed and well formed blood vessels.
HO-1 induction is necessary for efficient wound closure in
diabetic mice [48] and its role in angiogenesis is by regulating
154 V. Kant et al. / Cytokine 73 (2015) 144–155the synthesis/activity of VEGF and SDF-1a [49]. So, increased
expression of HO-1 in SP-treated group further added to the poten-
tial of SP in neovascularization and faster wound healing in diabet-
ic rats. The eNOS and its bioactive product nitric oxide (NO) are
also well-established proangiogenic molecules and this
endothelial-derived NO is vital for maintenance of proper vasodila-
tory nature and regulation of an anti-proliferative and
anti-apoptotic state for endothelial cells [50]. In consequence, in
the present study, the decreased expression of eNOS in control
group resulted in reduced and frustrated angiogenesis, which
was restored in SP-treated rats. In previous studies, the inhibition
or genetic disruption of eNOS has resulted in delayed wound clo-
sure [51] and cutaneous eNOS expression has been reported to
be significantly decreased in STZ-induced type 1 diabetic animals
[52].
The enzymes primarily involved in the degradation of extra cel-
lular matrix (ECM) are the MMPs. Disruption in the synthesis of
MMPs and/or alteration in the balance between enzymes and their
inhibitors have been shown to cause disorganization of the ECM
[53]. Hence, in present study, decreased expression of MMP-9
(Fig. 4B) in the SP-treated group was responsible for well formed
ECM and granulation tissue formation. Previous study in diabetics
has shown that activation of MMP expression is consistent with a
pattern associated with increased degradation of ECM [54].
Additionally, decreased expression of TGF-b in control group fur-
ther added to the increased expression of MMP-9. It has been
reported that most MMP genes have TGF-b inhibitory elements
in their promoter regions and their expression is decreased by
TGF-b [55].
Contraction speeds up the wound healing [56]. So, increased
wound contraction in SP-treated group (Fig. 1B), as compared to
control and gel-treated groups on different days, further supports
the fast healing in SP-treated rats. Re-epithelialization also increas-
es the wound contraction and in the present study, well formed
epithelial layer was present in SP-treated group on day 14
(Fig. 5A). TGF-b also has a chemoattractant effect on fibroblasts
and stimulates their proliferation [57]. Thus, in present study,
increased expression of TGF-b1 in SP-treated wound was responsi-
ble for the marked proliferation of fibroblasts, which in turn cause
more collagen deposition. Collagen deposition is indispensable for
granulation tissue formation and it also plays role in
re-epithelization in skin-wound repair process. As evident from
H&E (Fig. 5A) as well as picrosirius red staining (Fig. 8A) in our
study, collagen deposition, organization and orientation were bet-
ter in SP-treated group. Picrosirius red staining also revealed that
collagen fraction was more in SP-treated group (Fig. 8B). TNF-a
application causes reduction in the expression of collagen, which
further decreases the tensile strength of the wound [58]. Also,
there is a sharp antagonism among the pro-synthetic role of
TGF-b1 and the opposite effect of TNF-a in terms of ECM deposi-
tion, wound contraction and maturation. TNF-a inhibits Smad
phosphorylation through the c-Jun N-terminal kinase (JNK) path-
way and reduces the transcription of TGF-b1 [59]. Significantly
decreased TNF-a and increased TGF-b1 in SP-treated group in this
study suggest that SP efficiently controlled the balance between
TNF-a and TGF-b1 for better granulation tissue formation. In agree-
ment to earlier finding [60], the reduced microvessel density and
lumen size in SP-treated group on day 19 was due to the deposition
of compact and mature collagen fibers which in turn compressed
the small blood vessels and reduced their perimeter, so that the
endothelial cells go through apoptosis to form the less vascular
scar.
Diabetes also contributes to impaired axon sprouting in
experimental rat models [61]. GAP-43 is a marker of regeneration
and remodeling of the nerve fibers [62,63]. The expression of
GAP-43 immunoreactive fibers decreases in diabetic patients[64]. In the present study, increased expression of GAP-43 positive
fibers in SP-treated rats revealed better regeneration and remodel-
ing of the axons.
In conclusion, topical SP treatment caused faster as well as
organized healing of cutaneous wounds in diabetic rats.
Up-regulation of various angiogenic genes like VEGF, TGF-b1,
eNOS and HO-1, and stimulation of proliferative phase with
marked fibroblast proliferation and collagen deposition are
suggestive of improved healing by SP application. So, SP appears
to possess great potential in treating cutaneous wounds in diabetics.Acknowledgements
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